# US 2023/0265071 A1 · Aryl compounds and pharmaceutical compositions that modulate ikzf2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265071 A1
- Document ID: US20230265071A1
- Status: Published application
- Kind: A1
- Application number: 18/052,462
- Filed: 2022-11-03
- Published: 2023-08-24
- Earliest claimed: 2021-07-09
- Assignees: Plexium, Inc.
- Applicants: Plexium, Inc.
- Inventors: Pengyu Yang; Simon Bailey
- Web page: https://patentgrep.com/patent/US20230265071A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/84: involving inorganic compounds or pH
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are compounds and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2). The compounds are of formula I:

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A compound selected from:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 33 (depends on 32)

The compound of claim 32, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 34 (depends on 32)

The compound of claim 32, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 35 (depends on 32)

The compound of claim 32, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 36 (depends on 32)

The compound of claim 32, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 37 (depends on 32)

The compound of claim 32, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 38 (depends on 32)

The compound of claim 32, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 39 (depends on 32)

The compound of claim 32, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 40 (depends on 32)

The compound of claim 32, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 41

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound selected from:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 43 (depends on 41)

The pharmaceutical composition of claim 41, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 44 (depends on 41)

The pharmaceutical composition of claim 41, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 45 (depends on 41)

The pharmaceutical composition of claim 41, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 46 (depends on 41)

The pharmaceutical composition of claim 41, wherein the compound is:

### Claim 47 (depends on 41)

The pharmaceutical composition of claim 41, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 48 (depends on 41)

The pharmaceutical composition of claim 41, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 49 (depends on 41)

The pharmaceutical composition of claim 41, wherein the compound is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 50 (depends on 32)

A method for modulating cereblon activity, which method comprises contacting cereblon with an effective amount of a compound of claim 32, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, under conditions wherein cereblon is modulated.

### Claim 51 (depends on 41)

A method for modulating cereblon activity, which method comprises contacting cereblon with an effective amount of a pharmaceutical composition of claim 41, under conditions wherein cereblon is modulated.

### Claim 52 (depends on 32)

A method to degrade IKZF2 in a subject, which method comprises administering to said subject an effective amount of a compound of claim 32, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 53 (depends on 41)

A method to degrade IKZF2 in a subject, which method comprises administering to said subject an effective amount of a pharmaceutical composition of claim 41.

### Claim 54 (depends on 32)

A method to treat cancer in a subject in need thereof, which method comprises selecting a subject whose cancer is mediated at least in part by IKZF2 and administering to said subject an effective amount of a compound of claim 32, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.

### Claim 55 (depends on 41)

A method to treat cancer in a subject in need thereof, which method comprises selecting a subject whose cancer is mediated at least in part by IKZF2 and administering to said subject an effective amount of a pharmaceutical composition of claim 41.
